Compare Live Nation Entertainment, Inc. (LYV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Sana Biotechnology Inc — how do they compare? Live Nation Entertainment, Inc. trades at $170.86 (market cap $39.92B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Live Nation Entertainment, Inc. is far larger — about 47.7× Sana Biotechnology Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Sana Biotechnology Inc for 23 Days on average.
| LYV | SANA | |
|---|---|---|
Market Cap | $39.92B | $836.71M |
Volume | 1,982,609 | 4,507,444 |
Sector | Media | Health |
52-Week High | $188.46 | $5.92 |
52-Week Low | $125.61 | $2.68 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $42.13B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $172.10, up 0.74% today, with a bullish technical signal and strong analyst support. Revenue grew to $25.20B in 2025, though net income margin narrowed to 1.96%. Recent news highlights robust fan demand and strategic partnerships, while the stock faces high valuation multiples and regulatory scrutiny.
Outlook remains positive with a consensus price target of $208.18, but risks include elevated P/E of 117.49, debt levels, and legal uncertainties. Earnings momentum is mixed, with Q2 2026 beating estimates but Q1 and Q4 2025 missing, underscoring execution challenges amid growth.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
